Alzheimer's disease and BBB technology commercialization — the convergence of the largest neurology drug market with the greatest CNS drug delivery challenge — creating the primary commercial investment rationale for the Blood Brain Barrier Technology Market, with the FDA approvals of lecanemab (Leqembi — Eisai/Biogen, 2023) and donanemab (Kisunla — Eli Lilly, 2024) as...